The text resize requires Javascript to be enabled. Please enable Javascript on your browser or use the browser text size controls
NYSE
| MRK
34.7900
| -0.5100
3:50 PM ET | 07 Aug 2008
Product News
Read the latest news on Merck medicines and vaccines
Research & Development News
Read the latest news on Merck Research and Development
Corporate News
Merck to Fund U.S. VIOXX® Product Liability Resolution Program
Financial News
Merck Announces Fourth Quarter 2008 Dividend
2007 Annual Review
Achieving Results. Accelerating Discovery. Regaining Leadership.
SINGULAIR® (montelukast)
Statement: FDA early communication on safety review of SINGULAIR
MerckVaccines.com
Direct ordering, account management, and product information
FOSAMAX® (alendronate sodium)
Statement regarding Osteonecrosis of the Jaw
VIOXX Information Center
Information on the voluntary withdrawal of VIOXX® (rofecoxib)
This U.S. Web site is subject to
Merck.com Terms of Use
RSS
Podcast